{"title":"Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact","authors":"A. Almeman, H. Khalaf","doi":"10.4172/2155-9864.1000334","DOIUrl":null,"url":null,"abstract":"Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Disorders and Transfusion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9864.1000334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.